TVRD — Tvardi Therapeutics, Inc.

Cara Therapeutics Q4 2023 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Q4 2023 revenue was $3 million, down from $3.3 million in Q4 2022. This included $2.3 million from collaborative revenue related to KORSUVA injection and $0.7 million from royalties and milestone payments.
• KORSUVA Injection Sales: Generated net sales of $5 million in Q4, with a 22% increase in demand quarter-over-quarter, reflected by wholesaler shipments.
• Expenses: R&D expenses rose to $28.4 million from $26 million year-over-year, primarily due to increased clinical trial costs. G&A expenses were stable at $6.6 million.
• Cash Position: Cash, cash equivalents, and marketable securities totaled $100.8 million, down from $156.7 million in the previous year, primarily due to $92.1 million used in operating activities.
• Cash Runway: The company expects its cash position to fund operations into 2026, following a financing transaction with HealthCare Royalty.

2. Strategic Updates and Business Highlights

• Focus on Notalgia Paresthetica (NP): Cara has prioritized the development of oral difelikefalin for NP, a condition with significant unmet medical need and no approved therapies. The company believes this focus will enhance clinical and commercial success.
• Clinical Trials: Enrollment in the Phase 2/3 COURAGE I study for NP has been completed ahead of schedule, with top-line results expected in Q3 2024. The study aims to assess the efficacy of oral difelikefalin.
• Market Potential: Approximately 650,000 patients in the U.S. are diagnosed with NP, with a substantial number reporting dissatisfaction with current treatment options.

3. Forward Guidance and Outlook

• Clinical Milestones: Cara aims to report top-line efficacy and safety results from the COURAGE I trial in Q3 2024, which will inform the design of the pivotal Phase 3 study.
• Partnership Opportunities: While the company is currently focused on internal development, there is potential for partnerships in late-stage development, given the interest generated by recent publications.

4. Bad News, Challenges, or Points of Concern

• KORSUVA Injection Access: Following unfavorable reimbursement changes, the company anticipates that dialysis organizations will restrict access to KORSUVA, leading to a decline in revenue contributions from this product.
• Cash Utilization: The significant cash burn of $92.1 million in operating activities raises concerns about financial sustainability, although the company has extended its cash runway into 2026.

5. Notable Q&A Insights

• Clinical Program Size: The size of the Phase 3 program for NP will be determined based on results from the ongoing Part A study. The company aims to simplify the pivotal program by selecting one optimal dose.
• Placebo Effect Expectations: The company anticipates a slightly higher placebo response in the upcoming trial due to a larger study design and increased awareness, which could impact the interpretation of efficacy results.
• Quality of Life Measures: The company is still determining appropriate quality of life measures for NP patients, acknowledging that existing tools may not be relevant.

Overall, Cara Therapeutics is strategically focusing on the development of oral difelikefalin for NP, with promising clinical data and a clear cash runway, despite challenges related to KORSUVA injection and overall cash utilization.